Journal of the American Society of Nephrology · 2000 · 192 citations · 10 references
MedicineCardiologyNephrologyKidney TransplantationRenal PathophysiologyTransplant SurgeryCardiovascular DiseaseRenal DiseaseRenal Vascular DiseaseAtherosclerotic ProgressionCardiovascular Complications After TransplantationHomocysteine ElevationSerum Folate Status
Renal transplant recipients have disproportionately high rates of arteriosclerotic outcomes, and recent studies provided controlled evidence that clinically stable renal transplant recipients have an excess prevalence of hyperhomocysteinemia. Few studies suggest that hyperhomocysteinemia may be a cardiovascular risk factor in renal transplant recipients. In the study presented here, the association between atherosclerotic events and homocysteine concentrations was examined in 207 stable renal transplant recipients. The role of hyperhomocysteinemia was analyzed with respect to other known cardiovascular risk factors. The mean follow-up was 21.2 +/- 1.9 mo (range, 14 to 26). Mean total homocysteine (tHcy) was 21.1 +/-9.5 micromol/L and median concentration was 19 micromol/L. Seventy percent of patients (n = 153) were hyperhomocysteinemic (values >15 micromol/L). tHcy correlated negatively with folate concentration (r = -0.3; P < 0.01). tHcy was closely related to creatinine concentration (r = 0.54; P < 0.001). Cardiovascular disease events (CVE) including death were observed in 30 patients (14.5 %; 7.34 events per 1000 person-months of follow-up). Fasting tHcy values were higher in patients who experienced CVE (31.5 +/- 10.3 versus 17.8 +/- 7.5; P < 0.001). Cox regression analysis showed that tHcy was a risk factor for cardiovascular complications (relative risk [RR] 1.06; 95% confidence interval (95% CI), 1.04 to 1.09; P < 0.0001). This corresponds to an increase in RR for CVE of 6% per micromol/L increase in tHcy concentration. Age (RR 1.55; 95% CI, 1.09 to 2.19; P < 0.01) and creatinine concentration (RR 1.34; 95% CI, 1.08 to 1.66; P < 0.01) were also independent predictors for CVE. This study demonstrates that elevated fasting tHcy is an independent risk factor for the development of CVE in chronic stable renal transplant recipients. Randomized, placebo-controlled homocysteine studies of the effect of tHcy lowering on CVE rates are urgently required in this patient population.
10
The Metabolic Basis of Inherited Disease.
Annals of Internal Medicine · 1988 · 7.8K citations
Hyperhomocysteinemia: An Independent Risk Factor for Vascular Disease
Robert Clarke, Leslie Daly, Killian Robinson et al. · New England Journal of Medicine · 1991 · 2.2K citations · Full text
Cardiovascular disease after renal transplantation.
B L Kasiske, Carlos Guijarro, Ziad A. Massy et al. · Journal of the American Society of Nephrology · 1996 · 673 citations
Medicine, Nephrology, Surgery +14
Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients.
Philippe Chauveau, B. Chadefaux, M. Coudé et al. · PubMed · 1993 · 226 citations
Medicine, Cardiology, Nephrology +11